TLR3 plays significant roles against hepatitis B virus

Molecular Biology Reports

Volumn 41, Issue 5, 2014, Pages 3279-3286

  Karimi Googheri, Masoud ^a   Arababadi, Mohammad Kazemi ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

dsRNA; Polymorphism; Prolonged HBV infection; TLR3

Indexed keywords

INTERFERON; LIGAND; TOLL LIKE RECEPTOR 3;

HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; SIGNAL TRANSDUCTION;

HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I; LIGANDS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3;

EID: 84905714245     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3190-x     Document Type: Review

References (69)

1. Assar S, Arababadi MK, Ahmadabadi BN, Salehi M, Kennedy D (2012) Occult hepatitis B virus (HBV) infection: a global challenge for medicine. Clin Lab 58(11-12):1225-1230
2. Ayoobi F, Hassanshahi G, Zainodini N, Khorramdelazad H, Arababadi MK, Kennedy D (2013) Reduced expression of TRIF in chronic HBV infected Iranian patients. Clin Res Hepatol Gastroenterol. doi:10.1016/j.clinre.2012.11.005
3. Khorramdelazad H, Hassanshahi G, Ahmadabadi BN, Arababadi MK (2012) High serum levels of TGF-beta in Iranians with chronic HBV infection. Hepat Mon 12(11):e7581. doi:10.5812/hepatmon.7581
4. Chan HL, Jia J (2011) Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 26(Suppl 1):131-137
5. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Rezvani ME (2009) Association of exon 9 but not intron 8 VDR polymorphisms with occult HBV infection in south-eastern Iranian patients. J Gastroenterol Hepatol 25(1):90-93
6. Mendy ME, Welzel T, Lesi OA, Hainaut P, Hall AJ, Kuniholm MH, McConkey S, Goedert JJ, Kaye S, Rowland-Jones S, Whittle H, Kirk GD (2009) Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J Viral Hepat 27:27
7. Michielsen P, Ho E (2011) Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol Belg 74(1):4-8
8. Ahmadabadi BN, Hassanshahi G, Arababadi MK, Leanza C, Kennedy D (2012) The IL-10 promoter polymorphism at position -592 is correlated with susceptibility to occult HBV infection. Inflammation 35(3):818-821. doi:10.1007/s10753-011-9381-x
9. Khvalevsky E, Rivkin L, Rachmilewitz J, Galun E, Giladi H (2007) TLR3 signaling in a hepatoma cell line is skewed towards apoptosis. J Cell Biochem 100(5):1301-1312. doi:10.1002/jcb.21119 (Pubitemid 46480411)
10. Carpenter S, O'Neill L (2009) Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem J 422:1-10
11. Yu M, Lam J, Rada B, Leto TL, Levine SJ (2011) Doublestranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-dependent signaling: roles for dual oxidase 2-and caspasedependent pathways. J Immunol 186(2):1180-1188
12. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301(5633):640
13. Lai Y, Yi G, Chen A, Bhardwaj K, Tragesser BJ, Rodrigo AV, Zlotnick A, Mukhopadhyay S, Ranjith-Kumar CT, Kao CC (2011) Viral double-strand RNA-binding proteins can enhance innate immune signaling by toll-like Receptor 3. PLoS One 6(10):e25837. doi:10.1371/journal.pone.0025837
14. Arababadi MK, Ahmadabadi BN, Kennedy D (2012) Current information on the immunological status of occult hepatitis B infection. Transfusion 52(8):1819-1826
15. Arababadi MK, Pourfathollah AA, Jafarzadeh AA, Hassanshahi G (2010) Serum levels of Interleukin (IL)-10 and IL-17A in occult HBV infected South-East Iranian patients. Hepat Mon 10(1):31-35
16. Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30(1):16-34
17. Kawai T, Akira S (2006) Innate immune recognition of viral infection. Nat Immunol 7(2):131-137 (Pubitemid 43135878)
18. Beutler B (2008) Toll-like receptor genes. Genetic susceptibility to infectious diseases, pp. 165
19. Youn HS, Lee JY, Saitoh SI, Miyake K, Kang KW, Choi YJ, Hwang DH (2006) Suppression of MyD88-and TRIF-dependent signaling pathways of toll-like receptor by (S)-epigallocatechin-3-gallate, a polyphenol component of green tea. Biochem Pharmacol 72:850-859 (Pubitemid 44313886)
20. Muzio M, Bosisio D, Polentarutti N, D'amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P (2000) Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164(11):5998-6004 (Pubitemid 30389848)
21. Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR (2005) The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc Natl Acad Sci USA 102(31):10976-10980 (Pubitemid 41105978)
22. Choe J, Kelker MS, Wilson IA (2005) Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science 309(5734):581
23. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5(2):190-198. doi:10.1038/ni1028 (Pubitemid 38208361)
24. Nicodemus CF, Berek JS (2010) TLR3 agonists as immunotherapeutic agents. Immunotherapy 2(2):137-140. doi:10.2217/imt.10.8
25. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413(6857):732-738. doi:10.1038/35099560 (Pubitemid 33009951)
26. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D (2004) mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279(13):12542-12550. doi:10.1074/jbc.M310175200 (Pubitemid 38445825)
27. Matsumoto M, Seya T (2008) TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 60(7):805-812. doi:10.1016/j.addr. 2007.11.005
28. Gauzzi MC, Del Corno M, Gessani S (2010) Dissecting TLR3 signalling in dendritic cells. Immunobiology 215(9-10):713-723. doi:10.1016/j.imbio.2010.05. 008
29. McBride S, Hoebe K, Georgel P, Janssen E (2006) Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol 177(9):6122-6128 (Pubitemid 44628828)
30. Wu JF, Chen CH, Ni YH, Lin YT, Chen HL, Hsu HY, Chang MH (2012) Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in Taiwan. J Infect Dis 206(5):662-668. doi:10.1093/infdis/jis420
31. Chang WJ, Toledo-Pereyra LH (2012) Toll-like receptor signaling in liver ischemia and reperfusion. J Invest Surg 25(4):271-277. doi:10.3109/08941939. 2012.687802
32. Szatmary Z (2012) Molecular biology of toll-like receptors. Gen Physiol Biophys 31(4):357-366. doi:10.4149/gpb-2012-048
33. Li X, Jiang S, Tapping RI (2010) Toll-like receptor signaling in cell proliferation and survival. Cytokine 49(1):1-9. doi:10.1016/j.cyto.2009.08.010
34. Tuosto L (2011) NF-kappaB family of transcription factors: biochemical players of CD28 co-stimulation. Immunol Lett 135(1-2):1-9. doi:10.1016/j.imlet. 2010.09.005
35. Alsharifi M, Lobigs M, Regner M, Lee E, Koskinen A, Mullbacher A (2005) Type I interferons trigger systemic, partial lymphocyte activation in response to viral infection. J Immunol 175(7):4635-4640 (Pubitemid 41362003)
36. Maire M, Parent R, Morand AL, Alotte C, Trepo C, Durantel D, Petit MA (2008) Characterization of the double-stranded RNA responses in human liver progenitor cells. Biochem Biophys Res Commun 368(3):556-562. doi:10.1016/j.bbrc.2008.01.123
37. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z (2010) Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J Gen Virol 91(Pt 8):2080-2090. doi:10.1099/vir.0.020552-0
38. An BY, Xie Q, Lin LY, Shen HC, Jia NN, Wang H, Guo SM, Yu H, Guo Q (2007) Expression of Toll-like receptor 3 on peripheral blood dendritic cells in HBeAg positive patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 15(10):729-733
39. Ondondo BO, Brunham RC, Harrison WG, Kinyari T, Sheth PM, Mugo NR, Cohen CR (2009) Frequency and magnitude of Chlamydia trachomatis elementary body-and heat shock protein 60-stimulated interferon c responses in peripheral blood mononuclear cells and endometrial biopsy samples from women with high exposure to infection. J Infect Dis 199(12):1771-1779
40. Tjwa ET, van Oord GW, Biesta PJ, Boonstra A, Janssen HL, Woltman AM (2012) Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection. J Virol 86(8):4102-4109. doi:10.1128/JVI.07000-11
41. Wang K, Liu H, He Y, Chen T, Yang Y, Niu Y, Chen H, Chen Y, Liu J, Ye F, Lin S, Zhao Y (2010) Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum Immunol 71(10):950-956. doi:10.1016/j.humimm.2010.07.013
42. An BY, Xie Q, Wang H, Jia NN, Shen HC, Cai W, Yu H, Guo Q (2008) Expression and significance of interferon regulatory factor 3 of peripheral blood dendritic cells in HBV-infected patients. World Chin J Digest 16(17):1873-1879
43. Shi B, Ren G, Hu Y, Wang S, Zhang Z, Yuan Z (2012) HBsAg inhibits IFN-alpha production in plasmacytoid dendritic cells through TNF-alpha and IL-10 induction in monocytes. PLoS One 7(9):e44900. doi:10.1371/journal.pone.0044900
44. Liu WH, Liu JJ, Wu J, Zhang LL, Liu F, Yin L, Zhang MM, Yu B (2013) Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One 8(1):e55487. doi:10.1371/journal.pone.0055487
45. Al-Qahtani A, Al-Ahdal M, Abdo A, Sanai F, Al-Anazi M, Khalaf N, Viswan NA, Al-Ashgar H, Al-Humaidan H, Al-Suwayeh R, Hussain Z, Alarifi S, Al-Okail M, Almajhdi FN (2012) Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol 84(9):1353-1359. doi:10.1002/jmv.23271
46. Rong Y, Song H, You S, Zhu B, Zang H, Zhao Y, Li Y, Wan Z, Liu H, Zhang A, Xiao L, Xin S (2013) Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure. Inflammation 36(2):413-418. doi:10.1007/s10753-012-9560-4
47. Li G, Zheng Z (2013) Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumour Biol. doi:10.1007/s13277-013-0689-z
48. Gurtan AM, Sharp PA (2013) The role of miRNAs in regulating gene expression networks. J Mol Biol. doi:10.1016/j.jmb.2013.03.007
49. Hatao F, Muroi M, Hiki N, Ogawa T, Mimura Y, Kaminishi M, K-i Tanamoto (2004) Prolonged Toll-like receptor stimulation leads to down-regulation of IRAK-4 protein. J Leukoc Biol 76(4):904-908 (Pubitemid 39313728)
50. Chen M, Sällberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, Billaud J-N, Milich DR (2005) Immune tolerance split between hepatitis B virus precore and core proteins. J Virol 79(5):3016-3027 (Pubitemid 40270581)
51. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17(1):1-14
52. Yin W, Xu L, Sun R, Wei H, Tian Z (2012) Interleukin-15 suppresses hepatitis B virus replication via IFN-β production in a C57BL/6 mouse model. Liver Int 32(8):1306-1314
53. Wang J, Wang X, Liu P (1999) Detection of serum TNF-alpha, IFN-beta, IL-6 and IL-8 in patients with hepatitis B. World J Gastroenterol 5(1):38-40
54. Wang YD, Zhao CY, Wang W, Shen C, Lu HZ, Zhang L, Yu WY, Zhou JY, Yan WZ (2012) Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients. Hepatogastroenterology 59(115):680-686. doi:10.5754/hge12183
55. Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H (2013) Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol 48(3):397
56. Örmeci N (2003) Short-and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol 17(6):651-658
57. Sprinzl MF, Russo C, Kittner J, Allgayer S, Grambihler A, Bartsch B, Weinmann A, Galle PR, Schuchmann M, Protzer U, Bauer T (2013) Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment. J Viral Hepat. doi:10.1111/jvh.12189
58. Cho I-R, Oh M, Koh SS, Malilas W, Srisuttee R, Jhun BH, Pellegrini S, Fuchs SY, Chung Y-H (2012) Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor. Int J Mol Med 29(4):581-586
59. Wang X, Li Y, Mao A, Li C, Li Y, Tien P (2010) Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-β induction by disrupting the VISA-associated complex. Cell Mol Immunol 7(5):341-348
60. Roberts BJ, Dragon JA, Moussawi M, Huber SA (2012) Sex-specific signaling through Toll-Like Receptors 2 and 4 contributes to survival outcome of Coxsackievirus B3 infection in C57Bl/6 mice. Biol Sex Differ 3(1):25. doi:10.1186/2042-6410-3-25
61. Isogawa M, Robek MD, Furuichi Y, Chisari FV (2005) Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79(11):7269-7272. doi:10.1128/JVI.79.11.7269-7272.2005 (Pubitemid 40677357)
62. Heiberg IL, Winther TN, Paludan SR, Hogh B (2012) Pattern recognition receptor responses in children with chronic hepatitis B virus infection. J Clin Virol 54(3):229-234. doi:10.1016/j.jcv.2012.04.013
63. Chen L, Xu YY, Zhou JM, Wu YY, E Q, Zhu YY (2012) TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells. Oncol Rep 28(1):200-206. doi:10.3892/or 2012.1791
64. Schwarz K, Storni T, Manolova V, Didierlaurent A, Sirard JC, Rothlisberger P, Bachmann MF (2003) Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 33(6):1465-1470. doi:10.1002/eji. 200323919 (Pubitemid 36790406)
65. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46(6):1769-1778. doi:10.1002/hep.21897
66. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Daneshmandi S, Shamsizadeh A, Kennedy D (2011) Non-association of IL-12 +1188 and IFN-gamma +874 polymorphisms with cytokines serum level in occult HBV infected patients. Saudi J Gastroenterol 17(1):30-35
67. Dimitropoulou D, Karakantza M, Theodorou GL, Leonidou L, Assimakopoulos SF, Mouzaki A, Gogos CA (2013) Serum cytokine profile in patients with hepatitis B e antigen-negative chronic active hepatitis B and inactive hepatitis B virus carriers. World J Gastrointest Pathophysiol 4(1):24-27. doi:10.4291/wjgp.v4.i1. 24
68. Xiang X, Gui H, King NJ, Cole L, Wang H, Xie Q, Bao S (2012) IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol 90(6):611-619. doi:10.1038/icb.2011.79
69. Cao J, Zhang L, Huang S, Chen P, Zou L, Chen H, Xiang Y, Lai X, Ren G (2011) Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B. Microb Pathog 51(4):262-267. doi:10.1016/j.micpath.2011.06.003